A biological and pharmacologic phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumors (EORTC 16041).

被引：0

作者：

Van Herpen, Carla ^{[1
]}

Fiedler, Walter ^{[2
]}

Marreaud, Sandrine ^{[3
]}

Van Laarhoven, Hanneke ^{[1
]}

Peters, Marlies ^{[1
]}

Govaerts, Anne-Sophie ^{[3
]}

Toma, Salvatore ^{[4
]}

Bordignon, Claudio ^{[4
]}

Heerschap, Arend ^{[1
]}

Punt, Kees ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[2] Univ Hamburg Hosp, Hamburg, Germany

[3] Eortc Data Ctr, Brussels, Belgium

[4] Molmed SpA, Milan, Italy

来源：

MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3457S / 3457S

页数：1

共 50 条

[1] A phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumors (EORTC 16041)
Heerschap, A.
Fiedler, W.
Marreaud, S.
van Laarhoven, H.
Govaerts, A.
Peters, M.
Toma, S.
Bordignon, C.
Punt, K.
Van Herpen, C.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[2] Phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumours (EORTC 16041)
Van Herpen, C.
Fiedler, W.
Toma, S.
Marreaud, S.
Van Laarhoven, H.
Lasch, P.
Bogaerts, J.
Heerschap, A.
Bordignon, C.
Punt, C.
EJC SUPPLEMENTS, 2006, 4 (12): : 113 - 113
[3] Phase I and DCE-MRI evaluation of NGR-TNF, a novel vascular targeting agent, in patients with solid tumors (EORTC 16041)
van Laarhoven, H.
Fiedler, W.
Desar, I. M.
van Asten, S.
Marreaud, S.
Belli, R.
Bordignon, C.
Heerschap, A.
Punt, C. J.
van Herpen, C. M.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[4] Both NGR and TNF portions contribute to the biological activity of NGR-TNF vascular targeting agent in vivo
Alberici, Luca
Valentinis, Barbara
Porcellini, Simona
Di Matteo, Paola
Cota, Manuela
Zhou, Dan
Doglioni, Claudio
Bordignon, Claudio
Traversari, Catia
Rizzardi, Gian-Paolo
CANCER RESEARCH, 2011, 71
[5] Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors
Gregorc, Vanesa
De Braud, Filippo G.
De Pas, Tommaso M.
Scalamogna, Roberto
Citterio, Giovanni
Milani, Alessandra
Boselli, Sabrina
Catania, Chiara
Donadoni, Giovanni
Rossoni, Gilda
Ghio, Domenico
Spitaleri, Gianluca
Ammannati, Cristina
Colombi, Scialini
Caligaris-Cappio, Federico
Lambiase, Antonio
Bordignon, Claudio
CLINICAL CANCER RESEARCH, 2011, 17 (07) : 1964 - 1972
[6] Phase Ib study of NGR-hTNF, a selective vascular targeting agent (VTA), in combination with cisplatin in patients with refractory solid tumors
Citterio, G.
De Braud, F. G.
Gregorc, V.
De Pas, T. M.
Scalamogna, R.
Boselli, S.
Giovannini, M.
Caligaris-Cappio, F.
Lambiase, A.
Bordignon, C.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[7] Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors
OReilly, S
Grochow, LB
Donehower, RC
Chen, TL
Bowling, K
Hartman, NR
Struck, RF
Rowinsky, EK
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 1974 - 1984
[8] Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours
Citterio, G.
De Braud, F. G.
Gregorc, V.
De Pas, T. M.
Noberasco, C.
Boselli, S.
Giovannini, M.
Cappio, F. Caligaris
Lambiase, A.
Bordignon, C.
EJC SUPPLEMENTS, 2009, 7 (02): : 129 - 129
[9] A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors
De Braud, F. G.
Gregorc, V.
De Pas, T. M.
Citterio, G.
Scalamogna, R.
Boselli, S.
Giovannini, M.
Caligaris-Cappio, F.
Lambiase, A.
Bordignon, C.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[10] NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells
Di Matteo, P.
Hackl, C.
Jedeszko, C.
Valentinis, B.
Bordignon, C.
Traversari, C.
Kerbel, R. S.
Rizzardi, G-P
BRITISH JOURNAL OF CANCER, 2013, 109 (02) : 360 - 369

← 1 2 3 4 5 →